Keith Carter, MD
Ophthalmology · Iowa City, IANPI 1942201082
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,440 of the $54,020 with a category attached, or 69.3%. Genentech, Inc. accounts for 81.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $20,845 and has fallen 99.1% since, to $184 in 2025. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $1385.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$44K
- Genentech USA, Inc.$9K
- F. Hoffmann-la Roche AG$549
- Sun Pharmaceutical Industries Inc.$150
- Alcon$108
- Bausch & Lomb, A Division Of Bausch Health US, LLC$62
- plus $73 from 2 others
What the payments were for
- Consulting fees$37,44069%
- Speaking & faculty fees$3,0256%
- Travel & lodging$11,63222%
- Food & beverage$1,9234%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 16 | $43,938 |
| Genentech USA, Inc. | 7 | $9,141 |
| F. Hoffmann-la Roche AG | 8 | $549 |
| Sun Pharmaceutical Industries Inc. | 2 | $150 |
| Alcon | 3 | $108 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $62 |
| ANI Pharmaceuticals, Inc. | 1 | $38 |
| Edwards Lifesciences | 1 | $35 |
How this compares
$54,020 in reported general payments places this provider in the 95th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 118 | $910 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Iowa City
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Alina DumitrescuIowa City$57K
- Erin ShriverIowa City$43K
- James FolkIowa City$34K
- Marc Toeteberg-HarmsIowa City$21K
- Randy KardonIowa City$15K
- Elliott SohnIowa City$7K
- Sohan HayrehIowa City$5K
- Christopher SalesIowa City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.